Neoadjuvant Treatment in Resectable Pancreatic Cancer

NCT01900327 ↗

Phase 3 Terminated 32 enrolled University Medical Center Hamburg-Eppendorf Hannover Medical School · collab Heidelberg University · collab Klinikum Darmstadt · collab Klinikum Stuttgart · collab Ludwig-Maximilians - University of Munich · collab SRH Wald-Klinikum Gera GmbH · collab St. Josef Hospital Bochum · collab Staedtisches Klinikum Karlsruhe · collab Technical University of Munich · collab University Hospital Augsburg · collab University Hospital Freiburg · collab University Hospital Regensburg · collab University Hospital Schleswig-Holstein · collab University of Jena · collab University of Rostock · collab Universität des Saarlandes · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma

Timeline

Start: 2014-02
Primary completion: 2016-11-22
Completion: 2017-07

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment failure”

Publications

Tachezy M, Gebauer F, Petersen C, Arnold D, Trepel M, Wegscheider K, Schafhausen P, Bockhorn M, Izbicki JR, Yekebas E. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer. 2014 Jun 7;14:411. doi: 10.1186/1471-2407-14-411.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	300 mg/m2	—
Subject	Gemcitabine	Small molecule	1000 mg/m2	—